Cytosorbents (CTSO) Stock: Buy, Sell, or Hold?
CTSO - Cytosorbents Corp.
$5.27
-0.74 (-12.31%)
âŧ
5d:
+28.22%
30d:
+22.56%
90d:
+1363.89%
WAIT
LOW Confidence
Analysis Updated: Oct 23, 2026 12:00 AM ET
Earnings: Nov 12, 2026
18d
Get Alerted When CTSO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: CTSO is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: CTSO is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: CTSO is currently trading at $5.27, which is considered slightly high relative to its 30-day fair value range of $3.67 to $5.50.
Technical Outlook: Technically, CTSO is in a strong uptrend. Immediate support is located at $2.84, while resistance sits at $6.96. Short-term momentum is weak, with the stock down 12.3% recently.
Market Sentiment: CTSO scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $47.50 (+801.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CTSO is in a strong uptrend. Immediate support is located at $2.84, while resistance sits at $6.96. Short-term momentum is weak, with the stock down 12.3% recently.
Market Sentiment: CTSO scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $47.50 (+801.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$3.67 -
$5.50
Company Quality Score
31/100
(SELL)
Volume Confirmation
MODERATE
Confidence Score
31.6%
All Signals
- BEARISH: Weak technical setup (0/100)
- BEARISH: Downward momentum (-12.3%)
- BULLISH: Trading 801.3% below Wall St target ($47.50)
- WARNING: Composite score 31/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$3.67 -
$5.50
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$2.84
Resistance Level
$6.96
Current Trend
Strong Uptrend
Technical data as of
Oct 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
7.20
Wall Street Target
$47.50
(+801.3%)
Revenue Growth (YoY)
0.2%
Profit Margin
-48.9%
Share & Embed Analysis
Last updated: October 23, 2026 8:10 PM ET
Data refreshes hourly during market hours. Next update: 9:10 PM
Data refreshes hourly during market hours. Next update: 9:10 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CTSO showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
EW
Edwards Lifesciences Corp |
STRONG BUY
29 analysts |
$102 | 58 HOLD |
|
DXCM
DexCom Inc |
STRONG BUY
29 analysts |
$96 | 46 HOLD |
|
ABT
Abbott Laboratories |
STRONG BUY
28 analysts |
$121 | 52 HOLD |
|
SYK
Stryker Corporation |
STRONG BUY
29 analysts |
$363 | 37 SELL |
|
ZBH
Zimmer Biomet Holdings IâĻ |
HOLD
28 analysts |
$107 | 46 HOLD |
